Volume 25, Issue 2 (Summer 2017)                   Avicenna J Nurs Midwifery Care 2017, 25(2): 69-74 | Back to browse issues page


XML Persian Abstract Print


1- Hamadan University of Medical Sciences
2- Hamadan University of Medical Sciences , hosseini.mehdi54@gmail.com
3- shahid Beheshti University of Medical Sciences
Abstract:   (11061 Views)

Introduction: Diabetes mellitus is the fifth leading cause of death in most countries of the world. Diabetes causes disability, high cost of treatment, and increased mortality. The aim of this study was to determine the prevalence of chronic complications of diabetes and its related risk factors in patients referred to a diabetic's Center in Hamadan.

Methods: The study population of this cross-sectional descriptive study consisted of type I and type II diabetic patients referred to a diabetic's center in Hamadan and were selected by the census method. Extracted information of patients was analyzed using the Stata software version 11, with descriptive statistics and chi-square test and independent t test at a significance level of 5%.

Results: In this study, 347 patients with type II diabetes and 119 patients with type I diabetes were studied. In patients with type II diabetes, neuropathy and retinopathy complications were found in 57.34% and 47.55% of patients with type I diabetes, respectively. Prevalence of neuropathy and retinopathy complications was 37.65% and 13.44%, respectively with the highest prevalence amongst diabetes complications.

Conclusions: With regards to the high prevalence of diabetic complications in the study population, it is necessary to perform interventions, and regular control of blood pressure, cholesterol and blood glucose to reduce diabetic complications.

Persian Full-Text [PDF 185 kb]   (18419 Downloads)    
Type of Study: Systematic Review | Subject: Nursing
Received: 2016/03/12 | Accepted: 2016/08/31 | Published: 2017/02/8

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.